The FDA has given the go-ahead for Regeneron’s Eylea (aflibercept), an injectable drug for treating diabetic retinopathy.

The vascular endothelial growth factor (VEGF) inhibitor can treat all stages of the condition that can cause blindness or vision loss.

Eylea is the only VEGF inhibitor approved with two dosing options for diabetic retinopathy, allowing doctors to customize treatment to their patients' needs, the company said.